Preclinical data demonstrated that all human myeloma cell lines sensitive to venetoclax were restricted to the Cyclin D1 (CCND1) subgroup (80% harboring t(11;14)) and expressed elevated BCL-2:myeloid cell leukemia-1 (MCL-1) ratios29. Here, CCND1 is linked to plasma cell myeloma.